News - OBI Pharma 台灣浩鼎

2024.Jul.09

Corporate

OBI 's ADC Technology Platform GlycOBI® and Enzyme EndoSymeOBI® Two Trademarks Approved by Taiwan Intellectual Property Office

2024.Jun.28

Corporate

OBI Pharma shareholders’ meeting launches new company strategy and embraces transformation

2024.Jun.26

Media

OBI 's Proprietary Enzyme EndoSymeOBI™ Featured on Cover of Prestigious International Journal, JACS Au.

2024.Jun.21

Award & Certification

Dr. Heidi Wang, CEO of OBI Pharma, Inc., Selected as One of the Top 10 Managers of High-performing Enterprises by the Golden Torch Award

2024.Jun.12

Corporate

OBI Pharma announces Phase 1/2 study initiation for OBI-992, a TROP2-targeted antibody drug-Conjugate (ADC) for cancer therapy

2024.Jun.07

Corporate

OBI Pharma at BIO USA 2024

2024.Apr.11

Corporate

Poster Presentations at the AACR 2024 Annual Meeting for OBI-992 and GlycOBI™ ADC platform

2024.Mar.18

Corporate

OBI Pharma Announces Poster Presentations at the AACR 2024 Annual Meeting for OBI-992 and GlycOBI™ ADC platform.

2024.Mar.12

Corporate

OBI Pharma to present the Study Results of OBI-992 at the 14th World ADC London

2024.Mar.11

Corporate

OBI announces the termination of OBI-3424 Phase II trial

Announcements

Latest announcements

Events

Latest events